Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EPIC-CROWN-2

Financiado

Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC

"The highly contagious SARS-CoV-2 virus has generated an unprecedented pandemic with global dramatic public health and socio-economic consequences need an urgent mitigation. Despite the progression of the global use of efficient v... ver más

30/11/2023

FABENTECH

9M€

Presupuesto del proyecto: 9M€

Líder del proyecto

FABENTECH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 5 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-30

HORIZON-HLTH-2021-CORONA-01-01: Vaccines & therapeutic clinical tri... Expected Outcome:This topic aims at supporting activities that enable the conduct of vaccine & t...

I+D

Cerrada hace 3 años

0% 99% 100%

5 Participantes

FABENTECH

6.83M€ | Lider

FUNDACION PARA LA INVESTIGAC...

459.63K€ | Participante

HELLENIC INSTITUTE FOR THE S...

716.56K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-114481RB-I00 DESARROLLO, FUNCION INMUNE Y EFICACIA DE CANDIDATOS VACUNALE... 484K€ Cerrado

PID2020-117145RB-I00 NUEVAS TERAPIAS ANTIVIRALES E INMUNOMODULADORAS FRENTE AL SA... 303K€ Cerrado

PDC2021-121307-I00 IMPACTO DEL VECTOR MVA-ISG15 EN LA INFECION POR SARS-COV-2/C... 150K€ Cerrado

iMPact Novel, orally available immune modulator MP1032 with anti-SA... 8M€ Cerrado

RBDCOV RBD Dimer recombinant protein vaccine against SARSCoV2 10M€ Cerrado

BFU2011-23940 ANALISIS ESTRUCTURAL DE LOS MECANISMOS DE NEUTRALIZACION DEL... 347K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2021-11-11
Fecha Fin: 2023-11-30

Líder del proyecto

FABENTECH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 9M€

Descripción del proyecto "The highly contagious SARS-CoV-2 virus has generated an unprecedented pandemic with global dramatic public health and socio-economic consequences need an urgent mitigation. Despite the progression of the global use of efficient vaccines, an increased transmissibility of variants of concern (VOC) is predominantly observed. The reduced sensitivity of VOCs to neutralizing response could become a serious obstacle for efficient vaccination. In the absence of approved specific antiviral therapies for vaccinated-non-responders and the scarce anti-inflammatory therapies, passive immunotherapies with polyclonal immunoglobulins could be considered a part of the solution. The main objective of EPIC-CROWN is to rapidly assess, in multicentric clinical trials (phase IIa, 16 patients and IIb, 400 patients), an EMA-authorized antiviral immunotherapy based on potent and broad equine neutralizing anti-SARS-CoV-2 polyclonal F(ab’)2 antibodies in COVID-19 patients, including VOC carriers. In order to save lives and reduce the use and costs of critical care, this therapeutic solution expect to reduce at least by 50% ICUs admissions and a highly significant mortality rate of treated patients. To optimize the indications for the treatment, potency and breath of F(ab’)2 against variants will be assessed in in vitro and in an animal model as well as prospective studies will respectively be done on immune assessment in treated patients and on mitigation of exacerbated immune responses in vivo. Fab’entech will coordinate EPIC-CROWN-2 formed by outstanding experts in different project domains that include clinical trials (HISS, Greece), virology (IMAS12, Spain), and immunopathology models and mitigation (BNITM, Germany - IRD, France). Most of them having already been working together in European projects. Importantly, EPIC-CROWN-2 will be integrated as part of both the large European trial network EU-RESPONSE and the multinational European Adaptive Platform Trial Solid Act"". "

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores